Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Paclitaxel is the active ingredient of these drugs:
Australia Austria Brazil Canada Cyprus
Singapore
Brazil
Hong Kong New Zealand Singapore South Africa Tunisia
Austria Estonia Finland Ireland Lithuania
Singapore
Tunisia
Ecuador Tunisia
Austria Hong Kong Singapore South Africa Tunisia
Brazil
Singapore
Singapore
South Africa
Brazil
Brazil
New Zealand
Finland
Lithuania
Brazil
Ecuador
Cyprus
Australia
Ecuador
Ecuador
Brazil
Hong Kong Singapore
South Africa
Austria Estonia France Ireland Lithuania
Ecuador
South Africa
Lithuania
Hong Kong Poland Tunisia
Brazil
Brazil
Ecuador
Brazil Hong Kong Singapore South Africa
Ecuador
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):